# US 2026/0027210 A1 · Therapeutic combinations of titr effectors with radiation therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027210 A1
- Document ID: US20260027210A1
- Status: Published application
- Kind: A1
- Application number: 18/998,197
- Filed: 2023-07-27
- Published: 2026-01-29
- Earliest claimed: 2022-07-27
- Applicants: Varian Medical Systems, Inc.
- Inventors: Sophia PFISTER; Marta VILALTA; Ricky Anupam SHARMA; Yurun ZHANG; Sandra HATCHER; Vikash BHAGWANDIN; Ziyun DING
- Web page: https://patentgrep.com/patent/US20260027210A1

## CPC

- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61P 35/00: Antineoplastic agents
- C07K 16/2815: {against CD8}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- G01N 33/575: for cancer
- G01N 33/57515: of the breast
- G01N 33/5752: of the lungs
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This disclosure relates to therapeutic combinations of TITR effectors such as CCR8 targeting agents, radiation therapy and checkpoint inhibitors and methods of using the same for the treatment of cancer. The disclosure also relates to methods of stratifying a patient population for treating with the therapeutic combination.

## Claims

### Claim 1

A method of decreasing a population of tumor infiltrating regulatory T cell (TITR) cells in a subject, the method comprising administering to the subject a TITR effector and a radiation therapy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TITR effector is a CCR8 targeting agent.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the TITR effector and the radiation therapy are administered concurrently.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the TITR effector, the radiation therapy, or both are administered at least one time, at least two times, at least three times, at least four times or at least five times.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, comprising administering a checkpoint inhibitor selected from a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a TIM-3 inhibitor, a CEACAM inhibitor, a LAG-3 inhibitor, a VISTA inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a LAIR1 inhibitor, a CD160 inhibitor, a 2B4 inhibitor or a TGFR beta inhibitor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the checkpoint inhibitor is a PD-1 inhibitor.

### Claim 7 (depends on 5, 6)

The method of any one of claims 5-6, wherein the CCR8 targeting agent, the radiation therapy and/or the checkpoint inhibitor are administered concurrently or sequentially.

### Claim 8 (depends on 5, 6, 7)

The method of any one of claims 5-7, wherein the CCR8 targeting agent, the radiation therapy and/or the checkpoint inhibitor are administered at least one time, at least two times, at least three times, at least four times or at least five times.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the subject has a cancer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cancer is breast cancer, lung cancer, head and neck cancer, liver cancer, pancreatic cancer, brain cancer, colorectal cancer, or prostate cancer.

### Claim 11 (depends on 9, 10)

The method of any one of claims 9-10, wherein the cancer is resistant to the radiation therapy and/or the TITR effector.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the subject has previously been treated with the radiation therapy and/or the TITR effector.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the radiation therapy is electron radiation, proton radiation, photon radiation, a radiopharmaceutical, or brachytherapy.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the radiation therapy is ultra-high dose rate (FLASH) radiotherapy.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the method results in a decrease of about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the number of TITR cells in the subject relative to the number of TITR cells in the subject prior to the administration of the TITR effector and the radiation therapy.

### Claim 16

A method of treating cancer in a subject, the method comprising:
(a) obtaining a tumor sample from the cancer and a normal tissue sample;
(b) quantifying the expression level of at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20 genes, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110 genes, at least 115 genes, at least 120 genes, at least 125, at least 130 genes, at least 135 genes, at least 140 genes, at least 145, at least 150 genes, at least 155 genes, at least 160 genes, at least 165, at least 170 genes, at least 175 genes, or at least 180 genes; and
(c) administering to the subject a combination therapy comprising a TITR effector and a radiotherapy if a TITR gene signature is identified in the tumor sample compared to the normal tissue sample using an over-representation/enrichment method;
wherein the genes are selected from CCR8, CD80, CSF2RB, ENTPD1, EBI3, TNFRSF8, TNFRSF18, DUSP4, SDC4, LAPTM4B, TNFRSF4, SEC14L1, TNFRSF9, IRAK2, FNDC3B, IKZF4, IL1R2, NINJ1, SYNGR2, TNIP2, SSH1, ARHGEF12, GCNT1, NCF4, MAPKAPK2, RHBDD2, TRAF3, IRF5, ACOT9, HIVEP3, RFK, UEVLD, BCL2L1, FAM129A, BATF, RHOC, ZNRF1, PMAIP1, PLAGL2, MRPS6, IL1RL1, CREB3L2, CPD, PICALM, CCR5, CTNNA1, GALC, TTC39C, CYFIP1, STAT1, FURIN, TRAF1, GBP5, HIF1A, UBE2L6, PTPRJ, TNFRSF1B, REM, CAPN2, TRIM16, CD74, MAP2K3, TIGIT, CTSH, TAP1, SKAP2, ITGAE, JAK3, CAPG, OPTN, NDRG1, DUSP16, CD274, ICOS, GLRX, SAMSN1, ANXA4, MAPKAPK3, KATNAL1, CDKN1A, SNX9. PFKL, ABI2, ATP2B4, GM2A, PGM2, RIPK3, ISG15, NAMPT, MVP, GOT1, MXD1, TMBIM1, RORA, PCYT1A, N4BP1, LAMP2, TMEM159, OSBPL3, VIM, ATF3, CXCR3, ALDOC, PLP2, FAM126A, OXSR1, GRN, APAF1, ANK3, ANKRD55, ANXA2R, ATM, BAZ2B, CCR7, CD200, CECR1, CLUHP3, CXCR5, DPH5, EPHA1, EPHA4, FAM174B, FAM65B, FASTKD2, FOXP1, GIMAP4, GIMAP5, GIMAP6, GIMAP7, GIMAP8, GZMK, HIVEP2, IL10, INADL, INPP4B, IQGAP2, KCNA3, KIAA1009, KIAA2026, KLF3, KLRG1, LDLRAP1, LEF1, LMO7, LOC100130231, LPAR6, LRIG1, LY9, MAP3K3, MS4A1, NAP1L2, OBSCN, PAR-SN, PLAC8, PLAG1, PLEK, PLK2, PLXDC1, PRKCQ-AS1, RNF214, SERINC5, SESN1, SLAMF7, SLC16A7, SLC9A6, SMAD3, SPINT2, SSBP2, STXBP5, TCF7, TENM1, TMEM243, TRAT1, TTC21B, TXK, ZBTB10, ZNF248, ZNF480, ZNF737, ZNF780B, and ZNF91.

### Claim 17

A method for selecting a subject having a cancer for treatment with a combination therapy comprising a TITR effector and a radiation therapy, the method comprising:
(a) obtaining a tumor sample from the cancer and a normal tissue sample;
(b) quantifying the expression level of at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20 genes, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110 genes, at least 115 genes, at least 120 genes, at least 125, at least 130 genes, at least 135 genes, at least 140 genes, at least 145, at least 150 genes, at least 155 genes, at least 160 genes, at least 165, at least 170 genes, at least 175 genes, or at least 180 genes; and
(c) selecting the subject for treatment if a TITR gene signature is identified in the tumor sample compared to the normal tissue sample using an over-representation/enrichment method;
wherein the genes are selected from CCR8, CD80, CSF2RB, ENTPD1, EBI3, TNFRSF8, TNFRSF18, DUSP4, SDC4, LAPTM4B, TNFRSF4, SEC14L1, TNFRSF9, IRAK2, FNDC3B, IKZF4, IL1R2, NINJ1, SYNGR2, TNIP2, SSH1, ARHGEF12, GCNT1, NCF4, MAPKAPK2, RHBDD2, TRAF3, IRF5, ACOT9, HIVEP3, RFK, UEVLD, BCL2L1, FAM129A, BATF, RHOC, ZNRF1, PMAIP1, PLAGL2, MRPS6, IL1RL1, CREB3L2, CPD, PICALM, CCR5, CTNNA1, GALC, TTC39C, CYFIP1, STAT1, FURIN, TRAF1, GBP5, HIF1A, UBE2L6, PTPRJ, TNFRSF1B, REM, CAPN2, TRIM16, CD74, MAP2K3, TIGIT CTSH, TAP1, SKAP2, ITGAE, JAK3, CAPG, OPTN, NDRG1, DUSP16, CD274, ICOS, GLRX, SAMSN1, ANXA4, MAPKAPK3, KATNAL1, CDKN1A, SNX9. PFKL, ABI2, ATP2B4, GM2A, PGM2, RIPK3, ISG15, NAMPT, MVP, GOT1, MXD1, TMBIM1, RORA, PCYT1A, N4BP1, LAMP2, TMEM159, OSBPL3, VIM, ATF3, CXCR3, ALDOC, PLP2, FAM126A, OXSR1, GRN, APAF1, ANK3, ANKRD55, ANXA2R, ATM, BAZ2B, CCR7, CD200, CECR1, CLUHP3, CXCR5, DPH5, EPHA1, EPHA4, FAM174B, FAM65B, FASTKD2, FOXP1, GIMAP4, GIMAP5, GIMAP6, GIMAP7, GIMAP8, GZMK, HIVEP2, IL10, INADL, INPP4B, IQGAP2, KCNA3, KIAA1009, KIAA2026, KLF3, KLRG1, LDLRAP1, LEF1, LMO7, LOC100130231, LPAR6, LRIG1, LY9, MAP3K3, MS4A1, NAP1L2, OBSCN, PAR-SN, PLAC8, PLAG1, PLEK, PLK2, PLXDC1, PRKCQ-AS1, RNF214, SERINC5, SESN1, SLAMF7, SLC16A7, SLC9A6, SMAD3, SPINT2, SSBP2, STXBP5, TCF7, TENM1, TMEM243, TRAT1, TTC21B, TXK, ZBTB10, ZNF248, ZNF480, ZNF737, ZNF780B, and ZNF91.

### Claim 18 (depends on 16, 17)

The method of any one of claims 16-17, wherein the TITR effector is a CCR8 targeting agent.

### Claim 19 (depends on 16, 17, 18)

The method of any one of claims 16-18, wherein the radiation therapy is electron radiation, proton radiation, or photon radiation.

### Claim 20 (depends on 16, 17, 18, 19)

The method of any one of claims 16-19, wherein the radiation therapy is ultra-high dose rate (FLASH) radiotherapy.

### Claim 21 (depends on 16, 17, 18, 19, 20)

The method of any one of claims 16-20, wherein the cancer is breast cancer, lung cancer, head and neck cancer, liver cancer, pancreatic cancer, brain cancer, colorectal cancer, or prostate cancer.

### Claim 22

Use of a plurality of agents for quantifying the expression level of at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20 genes, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110 genes, at least 115 genes, at least 120 genes, at least 125, at least 130 genes, at least 135 genes, at least 140 genes, at least 145, at least 150 genes, at least 155 genes, at least 160 genes, at least 165, at least 170 genes, at least 175 genes, or at least 180 genes, in a cancer; and producing a report, wherein the report identifies whether the cancer has a TITR gene signature using an over-representation/enrichment method; and
wherein the genes are selected from CCR8, CD80, CSF2RB, ENTPD1, EBI3, TNFRSF8, TNFRSF18, DUSP4, SDC4, LAPTM4B, TNFRSF4, SEC14L1, TNFRSF9, IRAK2, FNDC3B, IKZF4, IL1R2, NINJ1, SYNGR2, TNIP2, SSH1, ARHGEF12, GCNT1, NCF4, MAPKAPK2, RHBDD2, TRAF3, IRF5, ACOT9, HIVEP3, RFK, UEVLD, BCL2L1, FAM129A, BATF, RHOC, ZNRF1, PMAIP1, PLAGL2, MRPS6, IL1RL1, CREB3L2, CPD, PICALM, CCR5, CTNNA1, GALC, TTC39C, CYFIP1, STAT1, FURIN, TRAF1, GBP5, HIF1A, UBE2L6, PTPRJ, TNFRSF1B, REM, CAPN2, TRIM16, CD74, MAP2K3, TIGIT, CTSH, TAP1, SKAP2, ITGAE, JAK3, CAPG, OPTN, NDRG1, DUSP16, CD274, ICOS, GLRX, SAMSN1, ANXA4, MAPKAPK3, KATNAL1, CDKN1A, SNX9. PFKL, ABI2, ATP2B4, GM2A, PGM2, RIPK3, ISG15, NAMPT, MVP, GOT1, MXD1, TMBIM1, RORA, PCYT1A, N4BP1, LAMP2, TMEM159, OSBPL3, VIM, ATF3, CXCR3, ALDOC, PLP2, FAM126A, OXSR1, GRN, APAF1, ANK3, ANKRD55, ANXA2R, ATM, BAZ2B, CCR7, CD200, CECR1, CLUHP3, CXCR5, DPH5, EPHA1, EPHA4, FAM174B, FAM65B, FASTKD2, FOXP1, GIMAP4, GIMAP5, GIMAP6, GIMAP7, GIMAP8, GZMK, HIVEP2, IL10, INADL, INPP4B, IQGAP2, KCNA3, KIAA1009, KIAA2026, KLF3, KLRG1, LDLRAP1, LEF1, LMO7, LOC100130231, LPAR6, LRIG1, LY9, MAP3K3, MS4A1, NAP1L2, OBSCN, PAR-SN, PLAC8, PLAG1, PLEK, PLK2, PLXDC1, PRKCQ-AS1, RNF214, SERINC5, SESN1, SLAMF7, SLC16A7, SLC9A6, SMAD3, SPINT2, SSBP2, STXBP5, TCF7, TENM1, TMEM243, TRAT1, TTC21B, TXK, ZBTB10, ZNF248, ZNF480, ZNF737, ZNF780B, and ZNF9L.

### Claim 23 (depends on 22)

The use of claim 22, wherein the cancer is breast cancer, lung cancer, head and neck cancer, liver cancer, pancreatic cancer, brain cancer, colorectal cancer, or prostate cancer.
